Literature DB >> 6489326

Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

W Wingender, K H Graefe, W Gau, D Förster, D Beermann, P Schacht.   

Abstract

The pharmacokinetics of ciprofloxacin (Bay o 9867) was examined after a single oral dose of 250 mg and a single intravenous dose of 100 mg respectively in six healthy male volunteers in an open, randomized crossover study. Although ciprofloxacin concentrations were measured in serum, plasma and urine by HPLC with fluorimetric detection and by microbiological assay, all pharmacokinetic calculations are based on the highly sensitive HPLC method only. The mean serum concentration of ciprofloxacin peaked approximately 1 h after the oral dose (0.94 mg/l). The elimination half-life was about 4 h and the renal clearance was 4.75 ml/min . kg; both were independent of the route of administration. The total clearance (9.62 ml/min . kg) was about twofold higher than the renal clearance. The volume of distribution of the central compartment was calculated to be 0.161 l/kg and the total volume at steady state was 2.0 l/kg. About 27% of the oral dose was excreted in urine, whereas the urinary recovery of the i.v. dose was 46%. The absolute bioavailability of ciprofloxacin was found to be approximately 60%. Ciprofloxacin appears to follow first-order, three compartment model kinetics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489326     DOI: 10.1007/bf01977494

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  10 in total

1.  Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.

Authors:  J Shimada; T Yamaji; Y Ueda; H Uchida; H Kusajima; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

2.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

3.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

4.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

  10 in total
  65 in total

1.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.

Authors:  M LeBel; M G Bergeron; F Vallée; C Fiset; G Chassé; P Bigonesse; G Rivard
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.

Authors:  D Fabre; F Bressolle; R Gomeni; C Arich; F Lemesle; H Beziau; M Galtier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

4.  Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.

Authors:  J H Yuk; C H Nightingale; K R Sweeney; R Quintiliani; J T Lettieri; R W Frost
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 5.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

6.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

7.  Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues.

Authors:  G J Gerstner; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

8.  Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.

Authors:  Luke Lin; Li-Wen Chang; Cheng-Yuan Tsai; Ching-Hung Hsu; David T Chung; William S Aronstein; Funmi Ajayi; Barbara Kuzmak; Robert A Lyon
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery.

Authors:  B Brismar; C Edlund; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.